Explore the comprehensive Pulmonary Arterial Hypertension (PAH) market forecast, covering 68 global markets. From $10.1 billion in 2024 to $17.9 billion by 2034, the 7 major markets lead with 48% ...

The incidence of pulmonary arterial hypertension (PAH) has increased worldwide over the past three decades, although death rates and disability-adjusted life year (DALY) rates related to the disease ...

Virtual echocardiography screening tool scores calculated via algorithm matched manually calculated scores and are promising ...

Lynn Hopkins of Ohio is happy she went with her gut and continued to explore her health issues, because it eventually led her ...

Chronic thromboembolic pulmonary hypertension (CTEPH) is the clinical term for high blood pressure in the lungs caused by ...

Hospitalizations for pulmonary hypertension have increased from 1980 to 2002, resulting in 200,000 hospitalizations for the condition as a primary or secondary diagnosis during that time. Accurate ...

If the cause of the pulmonary hypertension remains unexplained, chronic thromboembolism should be excluded as it can mimic PPH clinically. Fortunately, the ventilation-perfusion lung scan is a ...

Pulmonary arterial hypertension is a progressive, potentially fatal disease characterized by remodeling of the pulmonary vasculature, which results in increased pulmonary vascular resistance and ...

What’s more pulmonary arterial hypertension is rare, “a 25 per million disease,” and providers look for more common causes of shortness of breath, such as COPD, asthma, heart failure ...

Dietary changes may treat pulmonary hypertension Researchers show restricting two amino acids halts disease progression in rodent models Date: May 2, 2024 ...

Persistent pulmonary hypertension of the newborn (PPHN) is a circulatory condition that occurs soon after birth. It happens to new babies whose lung vessels aren’t open wide enough and have ...